At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 338 enrolled
Drug / intervention
S-1 +2 moredrug
Likely dose
S-1 40 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer
In Brief
A Phase 3 clinical trial evaluating S-1, Cisplatin, and 1 other intervention for Gastric Cancer. Completed, enrolled 338 participants across 9 sites.
Detailed Summary
A multicenter, randomized, open-label, phase III trial of S-1 plus cisplatin (3 weekly) versus S-1 plus oxaliplatin chemotherapy for the first-line treatment of advanced gastric cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartDec 2012
Primary CompletionOct 2014
Study CompletionOct 2015
TodayJul 2026
First PostedAug 23, 2012
Enrollment StartDec 1, 2012
Primary CompletionOct 1, 2014
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.9 years ago
Interventions
S-1drug
S-1 : 40 mg/m2, twice daily, Day 1-14
Cisplatindrug
60 mg/m2/day Day 1
Oxaliplatindrug
130 mg/m2/day Day 1